Advice
following a second resubmission assessed under the end of life and orphan equivalent process
bevacizumab (Avastin®) is accepted for restricted use within NHS Scotland.
Indication under review: In combination with carboplatin and paclitaxel, for the front-line treatment of advanced (International Federation of Gynaecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
SMC restriction: In patients with FIGO stage IV disease
Addition of bevacizumab to standard chemotherapy with carboplatin and paclitaxel increased progression-free survival.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice214KB (PDF)
Medicine details
- Medicine name:
- bevacizumab (Avastin)
- SMC ID:
- 806/12
- Indication:
- In combination with carboplatin and paclitaxel, for the front-line treatment of advanced (International Federation of Gynaecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 09 November 2015